NovaBay Pharmaceuticals Inc
XBER:B9P
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NovaBay Pharmaceuticals Inc
Change in Working Capital
NovaBay Pharmaceuticals Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NovaBay Pharmaceuticals Inc
AMEX:SDEV
|
Change in Working Capital
-$825k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Change in Working Capital
-$12.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Change in Working Capital
-$455m
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Change in Working Capital
-$5.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-81%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Change in Working Capital
-$7B
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-39%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Change in Working Capital
-$8.1B
|
CAGR 3-Years
-2 063%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-22%
|
|
NovaBay Pharmaceuticals Inc
Glance View
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. The company is headquartered in Emeryville, California and currently employs 29 full-time employees. The company went IPO on 2007-10-26. The firm develops and sells scientifically created and clinically proven eyecare and skincare products. Its product, Avenova Antimicrobial Lid & Lash Solution is used for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution. Its trademarks include Avenova, CelleRx, PhaseOne, NeutroPhase, DERMAdoctor, Kakadu C, AINT Misbehavin, KP Duty, and depictions of Dr. Audrey Kunin. Avenova Spray has broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. The Company, through its subsidiary DERMAdoctor, LLC, offers approximately 30 dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration, and keratosis pilaris.
See Also
What is NovaBay Pharmaceuticals Inc's Change in Working Capital?
Change in Working Capital
-825k
USD
Based on the financial report for Dec 31, 2025, NovaBay Pharmaceuticals Inc's Change in Working Capital amounts to -825k USD.
What is NovaBay Pharmaceuticals Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
-576%
Over the last year, the Change in Working Capital growth was -576%.
